To achieve proper PEP, you need enough volume to properly infiltrate all wounds.1
Having enough HRIG dose volume to treat all wounds is critical to proper post-exposure prophylaxis (PEP) administration and optimal infiltration. If HRIG volume is insufficient when administering into and around all eligible wounds, a patient will remain at risk of infection and death from the rabies virus. This is especially important for pediatric patients with lower body weights who frequently sustain larger, more severe wounds and need the maximum HRIG volume allowed.2-4
According to the CDC, proper PEP is most effective when following CDC–ACIP guidelines, which state, “…as much of the [HRIG] product as is anatomically feasible should be infiltrated into and around the wound.”1*
KEDRAB standard 150 IU/mL ensures a higher dose volume for complete wound infiltration to help avoid PEP failure4,5
Administering HRIG Is Like Putting Out an Uncontrolled House Fire
The Importance of HRIG Volume
To view additional information on the administration of KEDRAB, please click here.
To discuss why volume matters for you and your patients during HRIG administration,
*In order to infiltrate all wounds, you must have enough HRIG volume. Dosing of any HRIG must have a minimum volume to allow complete infiltration of all wounds, while also adhering to a body weight-based recommended dose of 20 IU/kg. Optimal infiltration of wounds is influenced by individual case characteristics, including the patient’s body weight, the nature of animal exposure and number/size of wounds, and the volume of the calculated HRIG dose.
References: 1. Centers for Disease Control and Prevention. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2010;59(2):1-9. 2. Howington GT, Nguyen H-B, Bookstaver PB, Akpunonu P, Swan JT. Rabies postexposure prophylaxis in the United States: opportunities to improve access, coordination, and delivery. PLoS Negl Trop Dis. 2021;15(7):e0009461. doi.org/10.1371/journal.pntd.0009461 3. Burke RV, Russo P, Sicilia M, et al. Epidemiology of rabies immune globulin use in paediatric and adult patients in the USA: a cross-sectional prevalence study. BMJ Open. 2022;12:e055411. doi:10.1136/bmjopen-2021-055411 4. Bookstaver PB, Akpunonu P, Nguyen HB, Swan JT, Howington GT. Administration of rabies immunoglobulin: Improving evidence-based guidance for wound infiltration. Pharmacotherapy. 2021;41(8):644-648. 5. KEDRAB [package insert]. Kedrion Biopharma Inc; 2021.